Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Ying Zhang, Hao Yan, Zhifei Xu, Bo Yang, Peihua Luo & Qiaojun He. (2019) Molecular basis for class side effects associated with PI3K/AKT/mTOR pathway inhibitors. Expert Opinion on Drug Metabolism & Toxicology 15:9, pages 767-774.
Read now
Read now
Evasio Pasini, Vincenzo Flati, Laura Comini, Adriana Olivares, Enrica Bertella, Giovanni Corsetti & Michele Vitacca. (2019) Mammalian Target of Rapamycin: Is It Relevant to COPD Pathogenesis or Treatment?. COPD: Journal of Chronic Obstructive Pulmonary Disease 16:1, pages 89-92.
Read now
Read now
José Luis González-Larriba, Pablo Maroto, Ignacio Durán, Julio Lambea, Luis Flores, Daniel Castellano & the Changing Group. (2017) The role of mTOR inhibition as second-line therapy in metastatic renal carcinoma: clinical evidence and current challenges. Expert Review of Anticancer Therapy 17:3, pages 217-226.
Read now
Read now
Steven E. Coutré, Jacqueline C. Barrientos, Jennifer R. Brown, Sven de Vos, Richard R. Furman, Michael J. Keating, Daniel Li, Susan M. O’Brien, John M. Pagel, Martin H. Poleski, Jeff P. Sharman, Nai-Shun Yao & Andrew D. Zelenetz. (2015) Management of adverse events associated with idelalisib treatment: expert panel opinion. Leukemia & Lymphoma 56:10, pages 2779-2786.
Read now
Read now
Articles from other publishers (24)
Sébastien Gendarme, Jean Pastré, Eliane M. Billaud, Laure Gibault, Romain Guillemain, Stéphane Oudard, Jacques Medioni, Agnès Lillo-Lelouet & Dominique Israël-Biet. (2023) Pulmonary toxicity of mTOR inhibitors. Comparisons of two populations: Solid organ recipients and cancer patients. Therapies 78:3, pages 267-278.
Crossref
Crossref
Rebecca Reed & Satomi Miwa. 2023. Biochemistry and Cell Biology of Ageing: Part III Biomedical Science. Biochemistry and Cell Biology of Ageing: Part III Biomedical Science
139
173
.
Anja Sipka, Thomas Weichhart & Sabine Mann. (2022) Pharmacological inhibition of the mTOR pathway alters phenotype and cytokine expression in bovine monocyte-derived dendritic cells. Veterinary Immunology and Immunopathology 249, pages 110441.
Crossref
Crossref
. (2022) Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer. Cancer Innovation 1:1, pages 25-54.
Crossref
Crossref
Kazuhiro Yamamoto, Takeshi Ioroi, Kazuaki Shinomiya, Ayaka Yoshida, Kenichi Harada, Masato Fujisawa, Tomohiro Omura, Yasuaki Ikemi, Shunsaku Nakagawa, Atsushi Yonezawa, Osamu Ogawa, Kazuo Matsubara, Takuya Iwamoto, Kohei Nishikawa, Sayaka Hayashi, Daichi Tohara, Yoji Murakami, Takanobu Motoshima, Hirofumi Jono & Ikuko Yano. (2022)
STAT3
Polymorphism Associates With mTOR Inhibitor-Induced Interstitial Lung Disease in Patients With Renal Cell Carcinoma
. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 29:1, pages 11-23.
Crossref
Crossref
Mitsuhiro Kato, Akiko Kada, Hideaki Shiraishi, Jun Tohyama, Eiji Nakagawa, Yukitoshi Takahashi, Tomoyuki Akiyama, Akiyoshi Kakita, Noriko Miyake, Atsushi Fujita, Akiko M. Saito & Yushi Inoue. (2022)
Sirolimus for epileptic seizures associated with focal cortical dysplasia type
II
. Annals of Clinical and Translational Neurology 9:2, pages 181-192.
Crossref
Crossref
Hanjie Mo, Khalid A. Jazieh, Daria Brinzevich & Jame Abraham. (2022) A Review of Treatment-Induced Pulmonary Toxicity in Breast Cancer. Clinical Breast Cancer 22:1, pages 1-9.
Crossref
Crossref
Aarti Sharma & Sidharth Mehan. (2021) Targeting PI3K-AKT/mTOR signaling in the prevention of autism. Neurochemistry International 147, pages 105067.
Crossref
Crossref
Sabino Strippoli, Livia Fucci, Antonio Negri, Daniela Putignano, Marco Luigi Cisternino, Gaetano Napoli, Ruggiero Filannino, Ivana De Risi, Angela Monica Sciacovelli & Michele Guida. (2020) Cellular analysis of bronchoalveolar lavage fluid to narrow differential diagnosis of checkpoint inhibitor-related pneumonitis in metastatic melanoma. Journal of Translational Medicine 18:1.
Crossref
Crossref
Sebastian Wolf, Michael Lauseker, Tobias Schiergens, Ulrich Wirth, Moritz Drefs, Bernhard Renz, Martin Ryll, Julian Bucher, Jens Werner, Markus Guba & Joachim Andrassy. (2020) Infections after kidney transplantation: A comparison of mTOR‐Is and CNIs as basic immunosuppressants. A systematic review and meta‐analysis. Transplant Infectious Disease 22:3.
Crossref
Crossref
Angela Esposito, Giulia Viale & Giuseppe Curigliano. (2019) Safety, Tolerability, and Management of Toxic Effects of Phosphatidylinositol 3-Kinase Inhibitor Treatment in Patients With Cancer. JAMA Oncology 5:9, pages 1347.
Crossref
Crossref
Christina Buchanan, Kate Lee & Peter Shepherd. (2019) For Better or Worse: The Potential for Dose Limiting the On-Target Toxicity of PI 3-Kinase Inhibitors. Biomolecules 9:9, pages 402.
Crossref
Crossref
Ricardo H. Alvarez, Rabih I. Bechara, Michael J. Naughton, Javier A. Adachi & James M. Reuben. (2018) Emerging Perspectives on mTOR Inhibitor-Associated Pneumonitis in Breast Cancer. The Oncologist 23:6, pages 660-669.
Crossref
Crossref
L. K. Schoch, A. Asiama, M. Zahurak, S. Shanbhag, J. Hurtt, K. Sawyer, L. J. Swinnen, N. Wagner-Johnston, R. J. Jones, R. F. Ambinder & Douglas E. Gladstone. (2017) Pharmacokinetically-targeted dosed everolimus maintenance therapy in lymphoma patients. Cancer Chemotherapy and Pharmacology 81:2, pages 347-354.
Crossref
Crossref
Florence Joly, Jean-Christophe Eymard, Laurence Albiges, Thierry Nguyen, Aline Guillot, Frederic Rolland, Dominique Spaeth, Brigitte Laguerre, Thierry Lebret, Nadia Kelkouli, Khemaies Slimane & Alain Ravaud. (2017) A prospective observational study on the evaluation of everolimus-related adverse events in metastatic renal cell carcinoma after first-line anti-vascular endothelial growth factor therapy: the AFINITE study in France. Supportive Care in Cancer 25:7, pages 2055-2062.
Crossref
Crossref
Shery Jacob & Anroop B. Nair. (2017) A review on therapeutic drug monitoring of the mTOR class of immunosuppressants: everolimus and sirolimus. Drugs & Therapy Perspectives 33:6, pages 290-301.
Crossref
Crossref
Vickie R. Shannon, George A. Eapen, Carlos A. Jimenez, Horiana B. Grosu, Rodolfo C. Morice, Lara Bashoura, Scott E. Evans, Roberto Adachi, Michael Kroll, Saadia A. Faiz, Diwakar D. Balachandran, Selvaraj E. Pravinkumar & Burton F. Dickey. 2016. Holland‐Frei Cancer Medicine. Holland‐Frei Cancer Medicine
1
29
.
Brian K. Kennedy & Juniper K. Pennypacker. (2016) Mammalian Target of Rapamycin: A Target for (Lung) Diseases and Aging. Annals of the American Thoracic Society 13:Supplement_5, pages S398-S401.
Crossref
Crossref
Xi Zhang, Yu-ge Ran & Kun-jie Wang. (2016) Risk of mTOR inhibitors induced severe pneumonitis in cancer patients: a meta-analysis of randomized controlled trials. Future Oncology 12:12, pages 1529-1539.
Crossref
Crossref
Annelieke E.C.A.B. Willemsen, Jan C. Grutters, Winald R. Gerritsen, Nielka P. van Erp, Carla M.L. van Herpen & Jolien Tol. (2016) mTOR inhibitor-induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm. International Journal of Cancer 138:10, pages 2312-2321.
Crossref
Crossref
Maria Shipkova, Dennis A. Hesselink, David W. Holt, Eliane M. Billaud, Teun van Gelder, Paweł K. Kunicki, Mercè Brunet, Klemens Budde, Markus J. Barten, Paolo De Simone, Eberhard Wieland, Olga Millán López, Satohiro Masuda, Christoph Seger, Nicolas Picard, Michael Oellerich, Loralie J. Langman, Pierre Wallemacq, Raymond G. Morris, Carol Thompson & Pierre Marquet. (2016) Therapeutic Drug Monitoring of Everolimus. Therapeutic Drug Monitoring 38:2, pages 143-169.
Crossref
Crossref
Sevdican Üstün, Caroline Lassnig, Andrea Preitschopf, Mario Mikula, Mathias Müller, Markus Hengstschläger & Thomas Weichhart. (2015) Effects of the mTOR inhibitor everolimus and the PI3K/mTOR inhibitor NVP-BEZ235 in murine acute lung injury models. Transplant Immunology 33:1, pages 45-50.
Crossref
Crossref
Brian M. SlomovitzYunyun JiangMelinda S. YatesPamela T. SolimanTaren JohnstonMaureen NowakowskiCharles LevenbackQian ZhangKari RingMark F. MunsellDavid M. GershensonKaren H. LuRobert L. Coleman. (2015) Phase II Study of Everolimus and Letrozole in Patients With Recurrent Endometrial Carcinoma. Journal of Clinical Oncology 33:8, pages 930-936.
Crossref
Crossref
Florian Lordick & Ulrich Hacker. 2015. Imaging of Complications and Toxicity following Tumor Therapy. Imaging of Complications and Toxicity following Tumor Therapy
3
15
.